By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) Announces Publication In The Lancet Neurology Of The Results Of The Phase III Randomized Study (NCT01313299) Showing Efficacy And Safety Of Dysport (Abobotulinumtoxina) In Adult Patients With Upper Limb Spasticity (ULS) 8/31/2015 11:02:48 AM
Ipsen (IPN.PA) Announces The Lancet Neurology Publishes Dysport Phase III Registration Trial Results In Adult Patients With Upper Limb Spasticity (ULS) 8/31/2015 10:39:39 AM
Ipsen (IPN.PA)’s Partner, Lexicon Pharma (LXRX), Announces Positive Results From TELESTAR Phase 3 Study Showing That Telotristat Etiprate Is Effective In The Treatment Of Carcinoid Syndrome Caused By Neuroendocrine Tumors Not Adequately Controlled By Somatostatin 8/3/2015 11:26:32 AM
Ipsen (IPN.PA): 2015 Half-Year Results 7/31/2015 7:57:33 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport(Abobotulinumtoxina) For Injection In The Treatment Of Upper Limb Spasticity In Adults In The United States 7/17/2015 9:17:28 AM
Ipsen (IPN.PA) Provides An Update On 2020 Strategy And Outlook At Investor Day 7/2/2015 11:18:20 AM
Ipsen (IPN.PA) Initiates A Share Buyback Program 6/3/2015 8:50:48 AM
Ipsen (IPN.PA) Confirms Its Eligibility For PEA-PME 6/2/2015 12:39:13 PM
Combined Shareholders’ Meeting Of IPSEN S.A. Held On 27 May 2015 5/29/2015 11:27:16 AM
Ipsen (IPN.PA) Strengthens Its Presence In The Oncology Field With The Acquisition Of Octreopharm Sciences, A Company Developing Innovative Radiopharmaceuticals For The Diagnosis And Treatment Of Neuroendocrine Tumors 5/19/2015 11:01:50 AM